Case report · 30 Jan 2025
Short communicationPublished 27 Jul 2021
Therapeutic Monoclonal Antibodies Targeting Cytokine Storm: Inclusion as a Future Treatment for the Severe Cases of COVID-19
1Department of Pharmaceutical Analysis, Institute of Pharmacy, Nirma University, Ahmedabad, India; 2Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Clinical studies have manifested immunotherapeutics as the most propitious for the management of COVID-19 so far. However, the springing up variants of SARS CoV-2 has positioned the role of preventive immunotherapeutics – vaccines in doubt. Even so therapeutic monoclonal antibodies, Tocilizumab – an IL-6 inhibitor and Ravulizumab – a complement protein C5a blocker which are in clinical trial phase –IV are ascertained to be effectual for the COVID-19 cytokine storm and are envisioned to be included as an approved treatment for the severe COVID-19 cases.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Cytokine Biology.
Case report · 30 Jan 2025
Inflammatory Diseases: Understanding, Causes, and Treatments
Perspective · 30 Jan 2025
Targeted Treatment: A Precision Approach to Healthcare
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Cytokine Biology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Shikha Patel”
- BylineArticles whose byline prints “Bhagawati Saxena”
- BylineArticles whose byline prints “Priti Mehta”